#1 Clinical Trials Search in Europe

Cobicistat

Cobicistat is being studied in several clinical trials as a pharmacokinetic booster to enhance the absorption and effectiveness of other medications. These trials are exploring its use with drugs like osimertinib, darunavir, atazanavir, and plixorafenib to potentially improve treatment outcomes for conditions including HIV, lung cancer, and glioma. The studies aim to evaluate how cobicistat affects drug levels in the body and its impact on safety and efficacy.

Table of Contents

What is Cobicistat?

Cobicistat, also known by its brand name Tybost, is a medication primarily used in the treatment of HIV (Human Immunodeficiency Virus) infection[1]. It’s important to note that Cobicistat itself is not an antiretroviral drug, meaning it doesn’t directly fight HIV. Instead, it plays a crucial role in enhancing the effectiveness of other HIV medications[2].

How Cobicistat Works

Cobicistat is known as a pharmacokinetic enhancer or booster. This means it helps other medications work better in your body. Specifically, Cobicistat works by inhibiting an enzyme in your liver called CYP3A4. This enzyme is responsible for breaking down many medications. By inhibiting CYP3A4, Cobicistat allows certain HIV medications to remain in your body longer and at higher concentrations, making them more effective[2][3].

Uses of Cobicistat

The primary use of Cobicistat is in the treatment of HIV-1 infection. It’s not used alone but always in combination with other antiretroviral drugs. Some key uses include:

  • Boosting the effects of HIV protease inhibitors like Darunavir and Atazanavir[4][5]
  • Enhancing the effectiveness of certain integrase inhibitors like Elvitegravir[1]
  • Allowing for once-daily dosing of some HIV medications, which can improve treatment adherence[2]

Cobicistat in Combination Therapies

Cobicistat is often used in fixed-dose combination (FDC) tablets, which means it’s combined with other HIV medications in a single pill. Some common combinations include:

  • Darunavir/Cobicistat (brand name Prezcobix)[4]
  • Atazanavir/Cobicistat (brand name Evotaz)[6]
  • Elvitegravir/Cobicistat/Emtricitabine/Tenofovir (brand name Stribild)[1]

These combination therapies can simplify HIV treatment by reducing the number of pills a patient needs to take each day.

Administration and Dosage

Cobicistat is typically taken orally in tablet form. The usual dose is 150 mg once daily, taken with food[7]. However, the exact dosage and administration can vary depending on the specific combination therapy and individual patient factors. Always follow your healthcare provider’s instructions and the prescription label carefully.

Side Effects and Safety

Like all medications, Cobicistat can cause side effects. Common side effects may include:

  • Nausea
  • Diarrhea
  • Headache
  • Mild rash

More serious side effects are rare but can occur. These may include kidney problems or changes in your immune system. It’s important to discuss any side effects with your healthcare provider[5].

Drug Interactions

Cobicistat can interact with many other medications due to its effect on liver enzymes. It’s crucial to inform your healthcare provider about all medications, supplements, and herbal products you’re taking. Some medications that may interact with Cobicistat include:

  • Certain cholesterol-lowering drugs
  • Some antidepressants
  • Certain heart medications
  • Some anticoagulants (blood thinners) like rivaroxaban and apixaban[8]

Ongoing Research

Research on Cobicistat is ongoing, exploring its potential uses beyond HIV treatment. For example, studies are investigating its use in boosting the effects of certain cancer medications[3][9]. These studies aim to improve the effectiveness and potentially reduce the required dosage of these medications, which could lead to fewer side effects and lower treatment costs.

Aspect Details
Primary Use Pharmacokinetic booster to enhance drug absorption and effectiveness
Medications Studied With Osimertinib, darunavir, atazanavir, plixorafenib, rivaroxaban
Conditions Targeted HIV, non-small cell lung cancer (NSCLC), BRAF-mutated glioma
Administration Oral tablet, typically 150 mg dose
Key Outcomes Measured Drug plasma concentrations, AUC, Cmax, safety profile, efficacy in disease treatment
Potential Benefits Increased drug exposure, possible dose reduction of primary medications, improved treatment outcomes
Safety Considerations Monitoring for adverse events, drug interactions, laboratory abnormalities
Novel Applications Enhancing CNS penetration of drugs, improving cost-effectiveness of expensive medications

FAQ

  • What is the main purpose of using cobicistat in these clinical trials? Cobicistat is primarily used as a pharmacokinetic booster to increase the absorption and effectiveness of other medications. It inhibits enzymes that break down certain drugs, allowing them to remain in the body longer and at higher concentrations.
  • Which medical conditions are being targeted in these cobicistat trials? The clinical trials involving cobicistat are targeting various conditions, including HIV, non-small cell lung cancer (NSCLC), and BRAF-mutated glioma. Cobicistat is being studied in combination with different drugs to potentially improve treatment outcomes for these diseases.
  • How is cobicistat administered in these trials? In most of the trials, cobicistat is administered orally as a tablet, often in combination with other medications. The typical dose is 150 mg, though some studies examine different dosing regimens or fixed-dose combinations with other drugs.
  • What are some of the potential benefits of using cobicistat? Potential benefits of using cobicistat include increased drug exposure of the primary medication, which may lead to improved efficacy, the possibility of reducing doses of expensive medications while maintaining effectiveness, and potentially improving treatment outcomes for conditions like HIV and cancer.
  • Are there any safety concerns associated with cobicistat use in these trials? While cobicistat is generally well-tolerated, the trials are monitoring for potential side effects and drug interactions. Safety assessments include tracking adverse events, laboratory abnormalities, and changes in vital signs. It's important to note that the safety profile may vary depending on the specific drug combination and patient population.

Ongoing Clinical Trials on Cobicistat

  • Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Norway Spain +1

  • Study of Lower Dose Olaparib Combined with Cobicistat to Improve Treatment Tolerance in Cancer Patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Modified Osimertinib Dosing with Cobicistat for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation

    Recruiting

    2 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Cobicistat, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Recruiting

    2 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Switching to Doravirine and Islatravir for People with HIV-1 on Antiretroviral Therapy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study on HIV Treatment Interruption in Children with Perinatal HIV Using Lamivudine and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Ireland Italy Spain

Glossary

  • Pharmacokinetic (PK) boosting: A strategy to enhance the absorption, distribution, or metabolism of a drug by co-administering it with another substance that affects its pharmacokinetics.
  • Bioequivalence: The absence of a significant difference in the rate and extent to which the active ingredient in pharmaceutical equivalents becomes available at the site of drug action when administered at the same dose under similar conditions.
  • Fixed-dose combination (FDC): A combination of two or more active pharmaceutical ingredients in a single dosage form, which is manufactured and distributed in fixed doses.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, calculated from a plot of drug concentration in blood plasma against time.
  • Maximum plasma concentration (Cmax): The peak concentration of a drug observed in the plasma after administration.
  • Half-life (t1/2): The time required for the concentration of a drug in the body to decrease by half.
  • CYP3A4: An important enzyme in the liver involved in the metabolism of many drugs.
  • ctDNA: Circulating tumor DNA, fragments of DNA from cancer cells that can be detected in blood or other bodily fluids.
  • BRAF V600E mutation: A specific genetic alteration found in some cancers, particularly melanoma and certain types of brain tumors.
  • RANO criteria: Response Assessment in Neuro-Oncology, a set of guidelines used to evaluate treatment response in brain tumors.

References

  1. https://clinicaltrials.gov/study/NCT02219217
  2. https://clinicaltrials.gov/study/NCT03683524
  3. https://clinicaltrials.eu/trial/study-on-modified-osimertinib-dosing-with-cobicistat-for-advanced-non-small-cell-lung-cancer-in-patients-with-egfr-mutation/
  4. https://clinicaltrials.gov/study/NCT02499978
  5. https://clinicaltrials.gov/study/NCT01837719
  6. https://clinicaltrials.gov/study/NCT05236738
  7. https://clinicaltrials.gov/study/NCT04718805
  8. https://clinicaltrials.gov/study/NCT03864406
  9. https://clinicaltrials.gov/study/NCT06385119